HC Wainwright & Co. Reiterates Buy on Theravance Biopharma, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Theravance Biopharma (NASDAQ:TBPH) and maintained a price target of $20.

May 29, 2024 | 10:58 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Theravance Biopharma and maintained a price target of $20, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $20 price target by a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and could lead to a short-term increase in TBPH's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100